Physician profile
Willliam A Jorge
NPI 1417003575
$1,706.63
in general payments reported to CMS, 2019-2025
11 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2021: $47.75 · 2022: $250 · 2023: $408 · 2024: $391 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,055 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,054.76 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $420.34 | 2019-2025 | Otezla, Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $317.78 | 2021-2025 | Lokelma, Farxiga |
| Ani Pharmaceuticals, INC. | $276.43 | 2023-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $159.68 | 2023-2025 | Acthar |
| Vifor Pharma, INC. | $158.23 | 2019-2025 | Veltassa |
| Janssen Pharmaceuticals, INC | $124.02 | 2019-2023 | Xarelto |
| Calliditas Therapeutics US INC. | $98.65 | 2023-2024 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $77.35 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.00 | 2023 | Cyltezo |
| Bayer Puerto Rico INC. | $25.00 | 2024 | Kerendia |
| Travere Therapeutics, INC. | $24.15 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Willliam Jorge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.